News

GJE recognised by Managing IP Stars 2019

We are delighted to have been listed as a leading firm in the 2019 edition of Managing IP. Every year, the publication independently researches practices in order to identify the world’s leading firms and individuals. The aspects assessed for the firm rankings include expertise, workload, market reputation/track record, outcomes achieved...

Read more

The President of the EPO turns up the heat on the Boards of Appeal in the debate over patentability of products of essentially biological processes

Following on from my previous report on the EPO Administrative Council’s new Rule 28(2) explicitly excluding products of “essentially biological processes” from patentability, this story has taken some interesting new turns. New Rule 28(2) was billed as a “clarification” of the meaning of Article 53(b) EPC but in February in...

Read more

Imago BioSciences announces $40M Series B financing led by Omega Funds

On 21 March, Imago BioSciences, Inc., a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, announced a $40 million Series B financing led by Omega Funds, a GJE client and leading international investment firm that creates and invests in life sciences companies. Proceeds from the financing will be used...

Read more

CJEU: No SPCs for new formulations of marketed active ingredients

The CJEU has provided further, somewhat limited, guidance on what pharmaceutical products may be awarded a Supplementary Protection Certificate (SPC), and the associated market exclusivity, in Europe. According to the CJEU, an earlier marketing authorisation issued for an active ingredient prevents an SPC being granted for a new formulation of...

Read more

GJE client Lundbeckfonden Emerge co-invests $50 million in SNIPR Biome Limited

On 11 March 2019, Lundbeckfonden Emerge announced the completion of a joint $50 million investment in SNIPR Biome Limited, alongside co-investors LSP, North-East Family Office and Wellington Partners. SNIPR Biome is pioneering its proprietary CRISPR technology to revolutionise the treatment of microbial diseases. The constructs developed by SNIPR can subvert elements...

Read more